دورية أكاديمية
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
| العنوان: | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. |
|---|---|
| المؤلفون: | Passaro, A, Wang, J, Wang, Y, Lee, S-H, Melosky, B, Shih, J-Y, Azuma, K, Juan-Vidal, O, Cobo, M, Felip, E, Girard, N, Cortot, AB, Califano, R, Cappuzzo, F, Owen, S, Popat, S, Tan, J-L, Salinas, J, Tomasini, P, Gentzler, RD, William, WN, Reckamp, KL, Takahashi, T, Ganguly, S, Kowalski, DM, Bearz, A, MacKean, M, Barala, P, Bourla, AB, Girvin, A, Greger, J, Millington, D, Withelder, M, Xie, J, Sun, T, Shah, S, Diorio, B, Knoblauch, RE, Bauml, JM, Campelo, RG, Cho, BC, MARIPOSA-2 Investigators |
| المساهمون: | Popat, Sanjay |
| بيانات النشر: | ELSEVIER |
| سنة النشر: | 2024 |
| المجموعة: | The Institute of Cancer Research (ICR): Publications Repository |
| مصطلحات موضوعية: | EGFR-mutated, NSCLC, amivantamab, lazertinib, post-osimertinib |
| جغرافية الموضوع: | England |
| الوصف: | BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. RESULTS: All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print-Electronic; S0923-7534(23)04281-3 -; application/pdf |
| اللغة: | English |
| تدمد: | 0923-7534 1569-8041 |
| العلاقة: | S0923-7534(23)04281-3; Annals of Oncology, 2023, pp. S0923-7534(23)04281-3 -; https://repository.icr.ac.uk/handle/internal/6113Test |
| DOI: | 10.1016/j.annonc.2023.10.117 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2023.10.117Test https://repository.icr.ac.uk/handle/internal/6113Test |
| حقوق: | https://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.A8436B1D |
| قاعدة البيانات: | BASE |
| تدمد: | 09237534 15698041 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.10.117 |